Modeling Statin-Induced Reductions of Cardiovascular Events in Primary Prevention: A VOYAGER Meta-Analysis

Area of Science:

• Cardiology
• Pharmacology
• Epidemiology

Background:

• Cardiovascular disease (CVD) remains a leading cause of mortality worldwide.
• Statins are a cornerstone therapy for managing dyslipidemia and reducing CVD risk.
• High-intensity statin regimens are frequently prescribed for patients with established atherosclerotic CVD (ASCVD).

Purpose of the Study:

• To estimate the cardiovascular (CV) risk reduction associated with commonly used high-intensity statins.
• To analyze the impact of specific statins like rosuvastatin (RSV) and atorvastatin (ATV) on CV event rates.

Main Methods:

• Utilized individual patient data from the VOYAGER database (n = 6,735) for patients with known ASCVD on high-intensity statin therapy.
• Employed the Cholesterol Treatment Trialists' Collaboration meta-analysis to predict risk reduction based on low-density lipoprotein cholesterol (LDL-C) reduction (38.7 mg/dL).

Main Results:

• Greatest risk reductions observed for major vascular events (rate ratios 0.55-0.60) and coronary heart disease death (rate ratios 0.58-0.64).
• Rosuvastatin 40 mg and atorvastatin 40 mg showed significant efficacy in reducing these critical CV outcomes.

Conclusions:

• High-intensity statin therapy demonstrates significant potential for CV risk reduction in patients with established ASCVD.
• These findings support the continued use of high-intensity statins for secondary prevention of cardiovascular events.